TICKERNERD
Menu
RANIRANIHealthcare · Biotechnology

RANI Stock Forecast: Rani Therapeutics Holdings, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$0.79
−2.46% on the day

The 5 Wall Street analysts covering Rani Therapeutics Holdings, Inc. hold a median 12-month price target of $6 — +657.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 68 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$114.1M
Ticker Nerd rank
68 / 100
Median analyst target
$6.00
Analysts covering
5
Revenue$1.7M
Operating income−$8.8M
Net income−$8.4M
Free cash flow−$9.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−0.5%
1M
−9.3%
YTD
−41.3%
1Y
+61.6%
From 52W high
−72.2%
From 52W low
+72.9%
$0.46
$2.85
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RANI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Rani Therapeutics Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
68 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
93
Accruals
76
Revisions
76
Size
74
Issuance
60
Momentum
58
Value
30
Quality
18
Volatility
10

Growth (93): Sales and profits are climbing, and climbing faster than before.

Volatility (10): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RANI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RANI, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26RANIHigh $11.00Median $6.00Low $5.00

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says5 analysts
5 Buy0 Hold0 Sell
Low $5.00Median $6.00High $11.00

The green dot is the last close — the median target sits +657.6% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
21 Aug 2026HC Wainwright & Co.ReiteratesBuy$11
18 Aug 2026Chardan CapitalInitiatesBuy$6.00
20 May 2026Canaccord GenuityMaintainsBuy—
20 May 2026Canaccord GenuityMaintainsBuy$5.00
1 Apr 2026Canaccord GenuityMaintainsBuy—
27 Mar 2026HC Wainwright & Co.ReiteratesBuy—
9 Jan 2026HC Wainwright & Co.ReiteratesBuy—
21 Oct 2025HC Wainwright & Co.AssumesBuy$11
20 Oct 2025Maxim GroupMaintainsBuy—
16 May 2025OppenheimerMaintainsOutperform—
3 Apr 2025HC Wainwright & Co.ReiteratesBuy—
26 Feb 2025Canaccord GenuityMaintainsBuy—
7 Feb 2025HC Wainwright & Co.ReiteratesBuy—
19 Nov 2024HC Wainwright & Co.ReiteratesBuy—
18 Oct 2024HC Wainwright & Co.ReiteratesBuy—
16 Aug 2024HC Wainwright & Co.MaintainsBuy—
2 Aug 2024OppenheimerInitiatesOutperform—
25 June 2024HC Wainwright & Co.ReiteratesBuy—
14 June 2024Maxim GroupInitiatesBuy—
13 June 2024Rodman & RenshawInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RANI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RANI vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Rani Therapeutics Holdings, Inc. returned +61.6% against +16.2% for the S&P 500, dividends included.

RANI vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400500Jan 26Apr 26Jul 26Oct 26RANIS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RANI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
0
Fundamentals

Rani Therapeutics Holdings, Inc. (RANI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.8×

Cheaper than 85% of US stocks

Price / sales
23.2×

Cheaper than 8% of US stocks

Price / book
2.3×

Cheaper than 39% of US stocks

EV / EBITDA
−1.7×

Cheaper than 71% of US stocks

Growth & margins
Revenue growth (YoY)
0.0%

Higher than 27% of US stocks

Earnings growth (YoY)
893.0%

Higher than 97% of US stocks

Gross margin
—
Operating margin
−516.9%

Higher than 8% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−172.1%

Higher than 8% of US stocks

Return on assets
−53.0%

Higher than 7% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Rani Therapeutics Holdings, Inc. (RANI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Rani Therapeutics Holdings, Inc. has a market value of $114.1M and an enterprise value of $54.6M.

  • Revenue in the twelve months to 30 June 2026: $4.9M. The latest quarter grew 0.0% year on year.

  • Net income over the same four quarters: −$33.4M, a −685.3% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.27.

  • Free cash flow in the twelve months to 30 June 2026: −$20.3M.

  • Shares outstanding: 112.5M.

  • Trailing P/E: −1.8×; forward P/E: −4.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Rani Therapeutics Holdings, Inc. employs 69 people — $71K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Oct 2026

Data provided by Twelve Data

Peers

RANI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RANIRani Therapeutics Holdings, Inc.$114.1M
68
UNCYUnicycive Therapeutics, Inc.$108.7M
43
LENZLENZ Therapeutics, Inc.$110.5M
25
VANIVivani Medical, Inc.$111.0M
47
GNLXGenelux Corp.$111.8M
19
BDTXBlack Diamond Therapeutics, Inc.$103.7M
56
PMVPPMV Pharmaceuticals, Inc.$112.5M
79

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Rani Therapeutics Holdings, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RANI news & analysis

Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)

GlobeNewsWire · 5 Oct 2026positive

Rani Therapeutics announced that its RaniPill platform technology has been accepted into the U.S. FDA's Emerging Technology Program (ETP). Acceptance into the program enables early FDA engagement to support development of the RaniPill platform.

Why it matters — A RANI watcher would care because early FDA engagement through the ETP could help streamline and support the regulatory development of the company's RaniPill platform technology.

Rani Therapeutics to Participate in Upcoming September Conferences

GlobeNewsWire · 8 Sept 2026neutral

Rani Therapeutics announced that its management team will participate in upcoming conferences in September. The announcement was made on September 8, 2026, by the clinical-stage biotherapeutics company focused on oral delivery of biologics.

Why it matters — The participation gives Rani watchers an opportunity for management to present and discuss the company's progress in oral biologic delivery with investors and industry peers.

This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday

Benzinga · 18 Aug 2026neutral

Top Wall Street analysts changed their outlooks on several names, with the article highlighting five analyst coverage initiations for Tuesday, including a Definium Therapeutics analyst beginning coverage on a bullish note. The item directs readers to a full analyst ratings page for all upgrades, downgrades, and initiations.

Why it matters — A RANI watcher would care because analyst coverage initiations and rating changes can draw investor attention and affect market sentiment toward stocks generally and within the biotech/therapeutics space.

Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline

MarketBeat · 16 Aug 2026positive

Rani Therapeutics outlined a strategy to expand the use of its RaniPill oral biologic-delivery platform through technology partnerships, selectively licensed product programs, and investments in manufacturing capacity.

Why it matters — The strategy signals how Rani plans to broaden its oral biologic platform beyond its current focus into areas such as obesity and immunology.

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

GlobeNewsWire · 13 Aug 2026positive

Rani Therapeutics reported its second quarter 2026 financial results and corporate update. The company advanced RT-114 in the clinic with first participants dosed in the Phase 1a expansion cohort and positive initial Phase 1a data showing oral bioavailability exceeding 150% relative to matched subcutaneous dosing. It also completed a $20 million registered direct offering, expanded its obesity pipeline through a collaboration with PegBio, and appointed Nicholas Maestas as CFO and Michelle Gilson to the Board of Directors.

Why it matters — A RANI watcher would care because the positive initial Phase 1a data for RT-114, pipeline expansion via the PegBio collaboration, and strengthened leadership signal continued progress on the company's oral-delivery platform.

FAQ

Frequently asked questions about RANI stock

What is the RANI stock price forecast for 2026-2027?

The 5 Wall Street analysts covering Rani Therapeutics Holdings, Inc. have a median 12-month price target of $6, with estimates ranging from $5 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RANI stock a buy right now?

Of the 5 analysts covering Rani Therapeutics Holdings, Inc., 5 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Rani Therapeutics Holdings, Inc. 68 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RANI?

As at 8 Oct 2026, Rani Therapeutics Holdings, Inc. ranks 68 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (93 of 100).

Will RANI stock go up?

No one can know that. What the data says: the median 12-month target from 5 analysts implies +657.6% from the last close, and Ticker Nerd's factor model ranks Rani Therapeutics Holdings, Inc. 68 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RANI stock forecast for 2030?

No analyst covering Rani Therapeutics Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RANI are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $5 to $11 over the next 12 months.

How has RANI stock performed over the past year?

Rani Therapeutics Holdings, Inc. returned +61.6% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Rani Therapeutics Holdings, Inc. do?

Rani Therapeutics Holdings, Inc. Class A Common Stock represents equity in Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery technologies for biologics and other drugs.

What is the latest news on RANI?

The most recent item we track (GlobeNewsWire, 5 Oct 2026): "Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)". Rani Therapeutics announced that its RaniPill platform technology has been accepted into the U.S. FDA's Emerging Technology Program (ETP). Acceptance into the program enables early FDA engagement to support development of the RaniPill platform.

Company

About Rani Therapeutics Holdings, Inc.

Rani Therapeutics Holdings, Inc. Class A Common Stock represents equity in Rani Therapeutics, a clinical-stage biotherapeutics company focused on oral delivery technologies for biologics and other drugs. The company’s core product is the RaniPill capsule, a proprietary platform designed to administer large-molecule therapies through the gastrointestinal tract, offering an alternative to injections and infusions. Rani Therapeutics develops this technology for use across multiple therapeutic areas, including peptides, proteins, antibodies, and oligonucleotides. Its business is centered on advancing drug-delivery solutions that may support patients, physicians, and healthcare systems by making biologic administration more convenient. The company operates in the biotechnology and health care life sciences sectors, where oral delivery platforms are an important area of innovation.

CEO Mr. Talat Imran · 69 employees · United States · https://www.ranitherapeutics.com